AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 104_CD Form_NN 20-F_JJ Information_NN 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 29_CD Employee_NN costs_NNS and_CC share_NN option_NN plans_NNS for_IN employees_NNS Employee_NN costs_VBZ The_DT average_JJ number_NN of_IN people_NNS employed_VBN by_IN the_DT Group_NNP is_VBZ set_VBN out_RP in_IN the_DT table_NN below_IN ._.
In_IN accordance_NN with_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, this_DT includes_VBZ part-time_JJ employees_NNS :_: Employees_NNS 2004 2003 2002_CD Average_JJ number_NN of_IN people_NNS employed_VBN by_IN the_DT Group_NNP in_IN :_: UK_NNP 11,500_CD 11,100_CD 10,900_CD Continental_NNP Europe_NNP 25,600_CD 23,900_CD 23,500_CD The_DT Americas_NNPS 18,500_CD 17,900_CD 17,800_CD Asia_NNP ,_, Africa_NNP &_CC Australasia_NNP 8,600_CD 8,100_CD 7,200_CD Continuing_VBG operations_NNS 64,200_CD 61,000_CD 59,400_CD The_DT number_NN of_IN people_NNS employed_VBN by_IN the_DT Group_NNP at_IN the_DT end_NN of_IN 2004_CD was_VBD 64,200_CD 2003_CD 62,600_CD ,_, 2002_CD 59,200_CD ._.
The_DT costs_NNS incurred_VBN during_IN the_DT year_NN in_IN respect_NN of_IN these_DT employees_NNS were_VBD :_: 2004 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD Salaries_NNS 4,078_CD 3,587_CD 3,022_CD Social_NNP security_NN costs_NNS 644 526 505_CD Pension_NN costs_NNS 266 272 220_CD Other_JJ employment_NN costs_NNS 303 360 246_CD 5,291_CD 4,745_CD 3,993_CD Employee_NN costs_NNS above_IN do_VBP not_RB include_VB severance_NN costs_NNS ._.
The_DT Directors_NNS believe_VBP that_IN ,_, together_RB with_IN the_DT basic_JJ salary_NN system_NN ,_, the_DT Groups_NNS employee_NN incentive_NN schemes_NNS provide_VBP competitive_JJ and_CC marketrelated_JJ packages_NNS to_TO motivate_VB employees_NNS ._.
They_PRP should_MD also_RB align_VB the_DT interests_NNS of_IN employees_NNS with_IN those_DT of_IN shareholders_NNS ,_, as_IN a_DT whole_JJ ,_, through_IN long_JJ term_NN share_NN ownership_NN in_IN the_DT Company_NN ._.
The_DT Groups_NNS current_JJ UK_NNP ,_, Swedish_NNP and_CC US_NNP schemes_NNS are_VBP described_VBN below_IN :_: other_JJ arrangements_NNS apply_VBP elsewhere_RB ._.
The_DT AstraZeneca_NNP UK_NNP Performance_NNP Bonus_NNP Plan_NNP Employees_NNS of_IN participating_VBG AstraZeneca_NNP UK_NNP companies_NNS are_VBP invited_VBN to_TO participate_VB in_IN this_DT bonus_NN plan_NN which_WDT rewards_VBZ strong_JJ individual_JJ performance_NN ._.
Bonuses_NNS are_VBP paid_VBN partly_RB in_IN the_DT form_NN of_IN Ordinary_NNP Shares_NNP in_IN the_DT Company_NN under_IN the_DT Inland_NNP Revenue_NN approved_VBD AstraZeneca_NNP AllEmployee_NNP Share_NNP Plan_NNP and_CC up_RB to_TO a_DT maximum_JJ annual_JJ value_NN of_IN 3,000_CD and_CC partly_RB in_IN cash_NN ._.
A_DT tax_NN efficient_JJ share_NN retention_NN scheme_NN ,_, under_IN which_WDT employees_NNS leave_VBP their_PRP$ bonus_NN shares_NNS in_IN trust_NN for_IN three_CD to_TO five_CD years_NNS ,_, forms_NNS part_NN of_IN the_DT All-Employee_NNP Share_NN Plan_NN ._.
The_DT Company_NN also_RB offers_VBZ UK_NNP employees_NNS the_DT opportunity_NN to_TO buy_VB Partnership_NNP Shares_NNP Ordinary_NNP Shares_NNP under_IN the_DT All-Employee_NNP Share_NN Plan_NN ._.
Employees_NNS may_MD invest_VB up_RP to_TO 1,500_CD over_IN a_DT 12_CD month_NN accumulation_NN period_NN and_CC purchase_NN Partnership_NNP Shares_NNP in_IN the_DT Company_NN with_IN the_DT total_JJ proceeds_NNS at_IN the_DT end_NN of_IN the_DT period_NN ._.
The_DT purchase_NN price_NN for_IN the_DT shares_NNS is_VBZ the_DT lower_JJR of_IN the_DT price_NN at_IN the_DT beginning_NN or_CC the_DT end_NN of_IN the_DT 12_CD month_NN period_NN ._.
A_DT tax_NN efficient_JJ share_NN retention_NN scheme_NN is_VBZ also_RB available_JJ in_IN respect_NN of_IN Partnership_NNP Shares_NNP ._.
At_IN the_DT Companys_NNPS AGM_NNP in_IN 2002_CD ,_, shareholders_NNS approved_VBD the_DT issue_NN of_IN new_JJ shares_NNS for_IN the_DT purposes_NNS of_IN the_DT All-Employee_NNP Share_NN Plan_NN ._.
The_DT AstraZeneca_NNP Executive_NNP Annual_JJ Bonus_NNP Scheme_NNP This_DT scheme_NN is_VBZ a_DT performance_NN bonus_NN scheme_NN for_IN Directors_NNS and_CC senior_JJ employees_NNS who_WP do_VBP not_RB participate_VB in_IN the_DT AstraZeneca_NNP UK_NNP Performance_NNP Bonus_NNP Plan_NNP ._.
Annual_JJ bonuses_NNS are_VBP paid_VBN in_IN cash_NN and_CC reflect_VB both_DT corporate_JJ and_CC individual_JJ performance_NN measures_NNS ._.
The_DT Remuneration_NNP Committee_NNP has_VBZ discretion_NN to_TO reduce_VB or_CC withhold_VB bonuses_NNS if_IN business_NN performance_NN falls_VBZ sufficiently_RB short_JJ of_IN expectations_NNS in_IN any_DT year_NN such_JJ as_IN to_TO make_VB the_DT payment_NN of_IN bonuses_NNS inappropriate_JJ ._.
The_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Scheme_NN and_CC the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Plan_NN UK_NNP employees_NNS may_MD make_VB regular_JJ monthly_JJ savings_NNS contributions_NNS over_IN a_DT three_CD or_CC five_CD year_NN period_NN and_CC may_MD apply_VB for_IN options_NNS to_TO acquire_VB AstraZeneca_NNP Ordinary_NNP Shares_NNP ._.
Further_JJ details_NNS are_VBP set_VBN out_RP below_IN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 105_CD 29_CD Employee_NN costs_NNS and_CC share_NN option_NN plans_NNS for_IN employees_NNS continued_VBD The_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN This_DT is_VBZ a_DT share_NN option_NN plan_NN for_IN employees_NNS of_IN participating_VBG AstraZeneca_NNP Group_NNP companies_NNS which_WDT was_VBD approved_VBN by_IN shareholders_NNS at_IN the_DT Companys_NNPS AGM_NNP in_IN 2000_CD ._.
The_DT first_JJ grant_NN of_IN options_NNS occurred_VBD in_IN August_NNP 2000_CD ._.
The_DT main_JJ grant_NN of_IN options_NNS in_IN 2004_CD under_IN the_DT plan_NN was_VBD in_IN March_NNP ,_, with_IN a_DT further_RBR ,_, smaller_JJR grant_NN in_IN August_NNP ._.
The_DT Remuneration_NNP Committee_NNP sets_VBZ the_DT policy_NN for_IN the_DT Companys_NNP operation_NN of_IN the_DT plan_NN ._.
Sweden_NNP In_IN Sweden_NNP an_DT all_DT employee_NN performance_NN bonus_NN plan_NN is_VBZ in_IN operation_NN ._.
The_DT plan_NN rewards_VBZ strong_JJ performance_NN at_IN corporate_JJ ,_, function_NN and_CC individual_JJ team_NN level_NN ._.
Bonuses_NNS for_IN corporate_JJ and_CC function_NN performance_NN are_VBP always_RB paid_VBN in_IN the_DT form_NN of_IN AstraZeneca_NNP Ordinary_NNP Shares_NNP ._.
Bonuses_NNS for_IN individual_JJ team_NN performance_NN may_MD be_VB paid_VBN in_IN Ordinary_NNP Shares_NNP or_CC in_IN cash_NN ,_, at_IN the_DT employees_NNS discretion_NN ._.
Existing_VBG Ordinary_NNP Shares_NNP are_VBP used_VBN to_TO pay_VB bonuses_NNS awarded_VBN under_IN the_DT plan_NN ._.
These_DT are_VBP purchased_VBN in_IN the_DT market_NN ._.
They_PRP must_MD be_VB left_VBN in_IN trust_NN for_IN three_CD years_NNS ._.
The_DT AstraZeneca_NNP Executive_NNP Annual_JJ Bonus_NNP Scheme_NNP and_CC the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN both_DT operate_VBP in_IN respect_NN of_IN relevant_JJ AstraZeneca_NNP employees_NNS in_IN Sweden_NNP ._.
US_NNP In_IN the_DT US_NNP ,_, there_EX are_VBP two_CD senior_JJ staff_NN incentive_NN schemes_NNS ,_, under_IN which_WDT either_CC AstraZeneca_NNP ADSs_NNPS or_CC stock_NN appreciation_NN rights_NNS related_VBN to_TO AstraZeneca_NNP ADSs_NNS are_VBP awarded_VBN to_TO participants_NNS ._.
There_EX are_VBP currently_RB approximately_RB 140_CD participants_NNS in_IN these_DT schemes_NNS ._.
AstraZeneca_NNP ADSs_NNP necessary_JJ to_TO satisfy_VB the_DT awards_NNS under_IN these_DT schemes_NNS are_VBP purchased_VBN in_IN the_DT market_NN and_CC no_DT subscriptions_NNS for_IN new_JJ Ordinary_NNP Shares_NNP have_VBP been_VBN involved_VBN ._.
The_DT AstraZeneca_NNP Share_NN Option_NN Plan_NNP operates_VBZ in_IN respect_NN of_IN relevant_JJ AstraZeneca_NNP employees_NNS in_IN the_DT US_NNP ._.
Share_NN option_NN plans_VBZ At_IN 31_CD December_NNP 2004_CD ,_, there_EX were_VBD options_NNS outstanding_JJ under_IN the_DT Zeneca_NNP 1994_CD Executive_NNP Share_NNP Option_NN Scheme_NN ,_, the_DT Astra_NNP Shareholder_NN Value_NNP Incentive_NNP Plan_NNP ,_, the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Scheme_NN ,_, the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Plan_NN and_CC the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN ._.
1_CD Summary_NNP of_IN the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NNP Eligibility_NNP Any_DT AstraZeneca_NNP employee_NN may_MD be_VB recommended_VBN from_IN time_NN to_TO time_NN for_IN the_DT grant_NN of_IN an_DT option_NN ._.
The_DT Remuneration_NNP Committee_NNP sets_VBZ the_DT policy_NN for_IN the_DT Companys_NNP operation_NN of_IN the_DT plan_NN including_VBG as_IN regards_VBZ which_WDT employees_NNS will_MD be_VB eligible_JJ to_TO participate_VB ._.
Grant_NNP of_IN options_NNS Options_NNS may_MD be_VB granted_VBN at_IN any_DT time_NN other_JJ than_IN during_IN a_DT close_JJ period_NN ._.
No_DT options_NNS may_MD be_VB granted_VBN after_IN the_DT fifth_JJ anniversary_NN of_IN the_DT approval_NN of_IN the_DT plan_NN by_IN shareholders_NNS until_IN the_DT Remuneration_NNP Committee_NNP has_VBZ reviewed_VBN the_DT plan_NN ._.
The_DT grant_NN of_IN options_NNS is_VBZ supervised_VBN by_IN the_DT Remuneration_NNP Committee_NNP which_WDT is_VBZ comprised_VBN wholly_RB of_IN Non-Executive_JJ Directors_NNS ._.
No_DT payment_NN is_VBZ required_VBN for_IN the_DT grant_NN of_IN an_DT option_NN ._.
Options_NNS may_MD be_VB granted_VBN over_IN AstraZeneca_NNP Ordinary_NNP Shares_NNP or_CC ADSs_NNP ._.
Acquisition_NNP price_NN The_DT price_NN per_IN Ordinary_NNP Share_NNP payable_JJ upon_IN the_DT exercise_NN of_IN an_DT option_NN will_MD not_RB be_VB less_JJR than_IN an_DT amount_NN equal_JJ to_TO the_DT average_NN of_IN the_DT middle-market_JJ closing_NN price_NN for_IN an_DT Ordinary_NNP Share_NN of_IN the_DT Company_NN on_IN the_DT London_NNP Stock_NNP Exchange_NNP on_IN the_DT three_CD consecutive_JJ dealing_VBG days_NNS immediately_RB before_IN the_DT date_NN of_IN grant_NN or_CC as_IN otherwise_RB agreed_VBN with_IN the_DT Inland_NNP Revenue_NN ._.
Where_WRB the_DT option_NN is_VBZ an_DT option_NN to_TO subscribe_VB ,_, the_DT price_NN payable_JJ upon_IN exercise_NN can_MD not_RB be_VB less_JJR than_IN the_DT nominal_JJ value_NN of_IN an_DT Ordinary_NNP Share_NN of_IN the_DT Company_NN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 106_CD Form_NN 20-F_JJ Information_NN 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 29_CD Employee_NN costs_NNS and_CC share_NN option_NN plans_NNS for_IN employees_NNS continued_VBD Exercise_NNP of_IN options_NNS An_DT option_NN will_MD normally_RB be_VB exercisable_JJ between_IN three_CD and_CC 10_CD years_NNS following_VBG its_PRP$ grant_NN provided_VBD any_DT relevant_JJ performance_NN condition_NN has_VBZ been_VBN satisfied_VBN ._.
Options_NNS may_MD be_VB satisfied_VBN by_IN the_DT issue_NN of_IN new_JJ Ordinary_NNP Shares_NNP or_CC by_IN existing_VBG Ordinary_NNP Shares_NNP purchased_VBD in_IN the_DT market_NN ._.
The_DT Remuneration_NNP Committee_NNP sets_VBZ the_DT policy_NN for_IN the_DT Companys_NNP operation_NN of_IN the_DT plan_NN including_VBG as_IN regards_VBZ whether_IN any_DT performance_NN target_NN s_PRP will_MD apply_VB to_TO the_DT grant_NN and_CC or_CC exercise_NN of_IN each_DT eligible_JJ employees_NNS option_NN ._.
Options_NNS normally_RB lapse_NN on_IN cessation_NN of_IN employment_NN ._.
Exercise_NN is_VBZ ,_, however_RB ,_, permitted_VBD for_IN a_DT limited_JJ period_NN following_VBG cessation_NN of_IN employment_NN either_CC for_IN reasons_NNS of_IN injury_NN or_CC disability_NN ,_, redundancy_NN or_CC retirement_NN ,_, or_CC at_IN the_DT discretion_NN of_IN the_DT Remuneration_NNP Committee_NNP ,_, and_CC on_IN an_DT amalgamation_NN ,_, take-over_NN or_CC winding-up_NN of_IN the_DT Company_NN ._.
2_CD Summary_NNP of_IN the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Scheme_NN and_CC the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Plan_NN The_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Scheme_NN was_VBD approved_VBN by_IN shareholders_NNS in_IN 1994_CD for_IN a_DT period_NN of_IN 10_CD years_NNS ._.
The_DT last_JJ grant_NN of_IN options_NNS under_IN this_DT scheme_NN was_VBD made_VBN in_IN September_NNP 2002_CD ._.
In_IN 2003_CD ,_, shareholders_NNS approved_VBD the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Plan_NN for_IN a_DT period_NN of_IN 10_CD years_NNS ._.
The_DT first_JJ grant_NN of_IN options_NNS under_IN this_DT plan_NN was_VBD made_VBN in_IN September_NNP 2003_CD ._.
The_DT following_JJ sections_NNS apply_VBP to_TO both_DT the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Scheme_NN and_CC the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Plan_NN ,_, which_WDT have_VBP broadly_RB similar_JJ rules_NNS ._.
Eligibility_NNP UK_NNP resident_NN employees_NNS of_IN participating_VBG AstraZeneca_NNP companies_NNS are_VBP automatically_RB eligible_JJ to_TO participate_VB ._.
Grant_NNP of_IN options_NNS Invitations_NNS to_TO apply_VB for_IN options_NNS may_MD be_VB issued_VBN within_IN six_CD weeks_NNS after_IN the_DT announcement_NN by_IN the_DT Company_NN of_IN its_PRP$ results_NNS for_IN any_DT period_NN and_CC at_IN other_JJ times_NNS in_IN circumstances_NNS considered_VBN to_TO be_VB exceptional_JJ by_IN the_DT Directors_NNS ._.
No_DT invitations_NNS may_MD be_VB issued_VBN later_RB than_IN 10_CD years_NNS after_IN the_DT approval_NN of_IN the_DT scheme_NN by_IN shareholders_NNS ._.
Options_NNS may_MD only_RB be_VB granted_VBN to_TO employees_NNS who_WP enter_VBP into_IN UK_NNP Inland_NNP Revenue_NN approved_VBD savings_NNS contracts_NNS with_IN the_DT savings_NNS body_NN nominated_VBN by_IN the_DT Company_NN ,_, under_IN which_WDT monthly_JJ savings_NNS of_IN a_DT fixed_VBN amount_NN currently_RB not_RB less_JJR than_IN 5_CD nor_CC more_JJR than_IN 250_CD are_VBP made_VBN over_RP a_DT period_NN of_IN three_CD or_CC five_CD years_NNS ._.
The_DT number_NN of_IN Ordinary_NNP Shares_NNP over_IN which_WDT an_DT option_NN is_VBZ granted_VBN will_MD be_VB such_JJ that_IN the_DT total_JJ amount_NN payable_JJ on_IN its_PRP$ exercise_NN will_MD be_VB the_DT proceeds_NNS on_IN maturity_NN of_IN the_DT related_JJ savings_NNS contract_NN ._.
No_DT payment_NN will_MD be_VB required_VBN for_IN the_DT grant_NN of_IN an_DT option_NN ._.
Individual_JJ participation_NN Monthly_JJ savings_NNS by_IN an_DT employee_NN under_IN all_DT savings_NNS contracts_NNS linked_VBN to_TO options_NNS granted_VBN under_IN any_DT SAYE_NNP scheme_NN may_MD not_RB exceed_VB 250_CD or_CC such_JJ lower_JJR amounts_NNS as_IN may_MD be_VB determined_VBN by_IN the_DT Directors_NNS ._.
Acquisition_NNP price_NN The_DT price_NN per_IN Ordinary_NNP Share_NNP payable_JJ upon_IN the_DT exercise_NN of_IN an_DT option_NN will_MD not_RB normally_RB be_VB less_JJR than_IN the_DT higher_JJR of_IN :_: a_DT 90_CD %_NN of_IN the_DT arithmetical_JJ average_NN of_IN the_DT middle-market_JJ quotations_NNS for_IN an_DT Ordinary_NNP Share_NN on_IN the_DT London_NNP Stock_NNP Exchange_NNP on_IN three_CD consecutive_JJ dealing_VBG days_NNS shortly_RB before_IN the_DT date_NN on_IN which_WDT invitations_NNS to_TO apply_VB for_IN options_NNS are_VBP issued_VBN provided_VBN that_IN no_DT such_JJ day_NN may_MD fall_VB before_IN the_DT Company_NN last_JJ announced_VBD its_PRP$ results_NNS for_IN any_DT period_NN or_CC such_JJ other_JJ dealing_VBG day_NN or_CC days_NNS falling_VBG within_IN the_DT six_CD week_NN period_NN for_IN the_DT issue_NN of_IN invitations_NNS as_IN the_DT Directors_NNS may_MD decide_VB :_: and_CC b_NN the_DT nominal_JJ value_NN of_IN an_DT Ordinary_NNP Share_NN unless_IN the_DT option_NN is_VBZ expressed_VBN to_TO relate_VB only_RB to_TO existing_VBG Ordinary_NNP Shares_NNP ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 107_CD 29_CD Employee_NN costs_NNS and_CC share_NN option_NN plans_NNS for_IN employees_NNS continued_VBD Exercise_NNP of_IN options_NNS An_DT option_NN will_MD normally_RB be_VB exercisable_JJ only_RB for_IN six_CD months_NNS commencing_VBG on_IN the_DT third_JJ or_CC fifth_JJ anniversary_NN of_IN the_DT commencement_NN of_IN the_DT related_JJ savings_NNS contract_NN ._.
Options_NNS are_VBP satisfied_VBN by_IN the_DT issue_NN of_IN new_JJ Ordinary_NNP Shares_NNP ._.
Exercise_NN is_VBZ ,_, however_RB ,_, permitted_VBD for_IN a_DT limited_JJ period_NN irrespective_RB of_IN the_DT period_NN during_IN which_WDT the_DT option_NN has_VBZ been_VBN held_VBN following_VBG cessation_NN of_IN employment_NN in_IN certain_JJ compassionate_JJ circumstances_NNS or_CC where_WRB an_DT option_NN has_VBZ been_VBN held_VBN for_IN more_JJR than_IN three_CD years_NNS except_IN on_IN dismissal_NN for_IN misconduct_NN and_CC on_IN an_DT amalgamation_NN ,_, take-over_NN or_CC winding-up_NN of_IN the_DT Company_NN ._.
AstraZeneca_NNP has_VBZ chosen_VBN to_TO avail_NN itself_PRP of_IN the_DT exemption_NN to_TO application_NN of_IN UITF17_NNP to_TO its_PRP$ SAYE_NNP schemes_NNS ._.
3_CD Summary_NNP of_IN the_DT Zeneca_NNP 1994_CD Executive_NNP Share_NNP Option_NN Scheme_NNP The_NNP Zeneca_NNP 1994_CD Executive_NNP Share_NNP Option_NN Scheme_NN was_VBD introduced_VBN in_IN 1994_CD ._.
The_DT last_JJ date_NN for_IN the_DT grant_NN of_IN options_NNS was_VBD 16_CD March_NNP 2000_CD and_CC the_DT scheme_NN has_VBZ been_VBN replaced_VBN by_IN the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN ._.
Options_NNS granted_VBN under_IN the_DT 1994_CD scheme_NN are_VBP normally_RB exercisable_JJ between_IN three_CD and_CC 10_CD years_NNS following_VBG grant_NN ,_, provided_VBD the_DT relevant_JJ performance_NN condition_NN has_VBZ been_VBN satisfied_VBN ._.
The_DT performance_NN condition_NN applicable_JJ to_TO the_DT 1994_CD scheme_NN was_VBD that_IN earnings_NNS per_IN share_NN must_MD have_VB grown_VBN by_IN at_IN least_JJS the_DT increase_NN in_IN the_DT UK_NNP Retail_NNP Price_NNP Index_NNP over_IN three_CD years_NNS plus_CC 3_CD %_NN per_IN annum_NN ._.
Satisfaction_NN of_IN this_DT condition_NN was_VBD tested_VBN annually_RB by_IN reference_NN to_TO the_DT audited_JJ financial_JJ statements_NNS ._.
All_DT options_NNS granted_VBN under_IN the_DT 1994_CD scheme_NN have_VBP become_VBN exercisable_JJ ,_, the_DT performance_NN conditions_NNS having_VBG been_VBN satisfied_VBN ._.
4_CD Summary_NNP of_IN the_DT Astra_NNP Shareholder_NN Value_NNP Incentive_NNP Plan_NNP In_IN 1996_CD ,_, Astra_NNP established_VBD a_DT stock_NN option_NN plan_NN for_IN some_DT 100_CD Astra_NNP employees_NNS in_IN key_JJ senior_JJ positions_NNS ._.
The_DT plan_NN is_VBZ no_RB longer_RB used_VBN for_IN the_DT grant_NN of_IN options_NNS and_CC has_VBZ been_VBN superseded_VBN by_IN the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN ._.
On_IN completion_NN of_IN the_DT merger_NN with_IN Zeneca_NNP ,_, options_NNS in_IN Astra_NNP shares_NNS granted_VBN under_IN the_DT plan_NN were_VBD replaced_VBN by_IN options_NNS to_TO acquire_VB a_DT number_NN of_IN AstraZeneca_NNP Ordinary_NNP Shares_NNP based_VBN on_IN the_DT exchange_NN ratio_NN used_VBN in_IN the_DT exchange_NN offers_VBZ used_VBN to_TO effect_VB the_DT AstraZeneca_NNP merger_NN ._.
The_DT ratio_NN of_IN AstraZeneca_NNP options_NNS granted_VBN in_IN respect_NN of_IN former_JJ Astra_NNP options_NNS was_VBD 0.5045_CD AstraZeneca_NNP options_NNS for_IN each_DT Astra_NNP option_NN held_VBD ._.
5_CD Summary_NNP of_IN the_DT Zeneca_NNP 1993_CD Senior_JJ Staff_NN Share_NN Option_NN Scheme_NNP The_NNP Zeneca_NNP 1993_CD Senior_JJ Staff_NN Share_NN Option_NN Scheme_NN was_VBD introduced_VBN at_IN the_DT time_NN of_IN the_DT demerger_NN of_IN Zeneca_NNP from_IN ICI_NNP in_IN 1993_CD ._.
The_DT last_JJ date_NN for_IN the_DT grant_NN of_IN options_NNS was_VBD 19_CD May_NNP 1994_CD and_CC the_DT scheme_NN was_VBD replaced_VBN by_IN the_DT Zeneca_NNP 1994_CD Executive_NNP Share_NNP Option_NN Scheme_NN ._.
At_IN 31_CD December_NNP 2004_CD ,_, there_EX were_VBD no_DT options_NNS outstanding_JJ under_IN this_DT scheme_NN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 108_CD Form_NN 20-F_JJ Information_NN 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 29_CD Employee_NN costs_NNS and_CC share_NN option_NN plans_NNS for_IN employees_NNS continued_VBD AstraZeneca_NNP Share_NNP Option_NN Plan_NN 1994_CD Scheme_NNP SAYE_NNP Schemes_NNPS ASVIP_NNP Shares_NNP under_IN Options_NNPS WAEP_NNP Options_NNPS WAEP_NNP Options_NNPS WAEP_NNP option_NN WAEP_NNP 000_CD pence_NN 000_CD pence_NN 000_CD pence_NN 000_CD SEK_NNP At_IN 1_CD January_NNP 2002_CD Options_NNPS outstanding_JJ 11,399_CD 3236_CD 9,938_CD 2636_CD 2,799_CD 2459 965 375_CD Movements_NNS during_IN 2002_CD Options_NNS granted_VBN 10,658_CD 3462_CD 2,721_CD 1756_CD Options_NNS exercised_VBN 22 3214 243 2175_CD 469 1888 206 317_CD Options_NNS forfeited_VBD 637 3298 406 2654_CD 986_CD 2735_CD Options_NNS lapsed_VBD Weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN during_IN the_DT year_NN 1186_CD 559_CD At_IN 31_CD December_NNP 2002_CD Options_NNPS outstanding_JJ 21,398_CD 3347_CD 9,289_CD 2647_CD 4,065_CD 1987 759 391_CD Movements_NNS during_IN 2003_CD Options_NNS granted_VBN 15,505_CD 2232 551 2211_CD Options_NNS exercised_VBN 52 2468 358 2423_CD 382 2137 151 311_CD Options_NNS forfeited_VBD 1,163_CD 3001 571 2695 282_CD 2192_CD 1_CD 318_CD Options_NNS lapsed_VBD Weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN during_IN the_DT year_NN 583_CD 658_CD At_IN 31_CD December_NNP 2003_CD Options_NNPS outstanding_JJ 35,688_CD 2874_CD 8,360_CD 2654_CD 3,952_CD 1988 607 411_CD Movements_NNS during_IN 2004_CD Options_NNS granted_VBN 10,741_CD 2529 550 2262_CD Options_NNS exercised_VBN 329 2787 586 2704_CD 113 2184 114 321_CD Options_NNS forfeited_VBD 1,964_CD 2886 285 2660 276_CD 2199_CD 10_CD 474_CD Options_NNS lapsed_VBD Weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN during_IN the_DT year_NN 650_CD 632_CD At_IN 31_CD December_NNP 2004_CD Options_NNPS outstanding_JJ 44,136_CD 2790_CD 7,489_CD 2650_CD 4,113_CD 2005 483 431_CD Range_NNP of_IN exercise_NN prices_NNS 1913p_VBP to_TO 891p_VB to_TO 1756p_VB to_TO 411SEK_CD to_TO 3487p_CD 2749p_CD 2971p_JJ 442SEK_NNP Weighted_NNP average_JJ remaining_VBG contractual_JJ life_NN 2,852_CD days_NNS 1,814_CD days_NNS 1,058_CD days_NNS 258_CD days_NNS Options_NNPS exercisable_JJ 10,706_CD 3203_CD 7,489_CD 2650 390 2373 483_CD 431_CD Weighted_JJ average_JJ exercise_NN price_NN
